Skip to main content
OpenTrials
Completed

NCT Number: NCT04731584

Systemic Inflammation During Recanalization of Cerebral Arterial Occlusion

Strokes management, secondary to proximal arterial occlusion, by endovascular thrombectomy (TM) is now well established. The immuno-inflammatory events of reperfusion after TM are discussed. Systemic inflammation is a major factor suggested to explain the limited recovery of the ischemic parenchyma. Understanding these phenomena is necessary before developing an immunomodulatory strategy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Infections Nervous System Diseases Systemic Infection Toxemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service d'Anesthésie Réanimation Hôpital - Neurologique/Groupement Est, Bron, France

Loading trial locations.

Who can participate

Only the study team can determine whether someone qualifies for participation.

GROUP "AVC" :

Inclusion criteria

  • Adults patient (s)
  • Ischemic stroke by occlusion of a middle cerebral artery (proximal portion M1)
  • Initial diagnostic MRI infusion
  • TM with complete reperfusion (TICI 2b, 2c or 3)
  • TM performed under local anesthesia +/- anxiolysis, or sedation including propofol
  • mRS prior to stroke <2
  • Barthel index <90
  • Included in the HIBISCUS cohort
  • Patient who was informed and did not object to participating in the study OR included through the emergency procedure then collection of his non-objection or that of his trusted person as soon as possible

Exclusion criteria

  • NIHSS awareness score> or = 2
  • Haemorrhagic complication before thrombectomy
  • Pregnant woman
  • Multiple vascular occlusions
  • Occlusions of posterior or anterior cerebral territories other than M1
  • Protected major
  • TM performed under general anesthesia
  • Other vital failure than neurological failure

GROUP "CONTROL" :

Inclusion criteria

  • Adults patient (s)
  • mRS <2
  • Barthel index <90
  • Requiring diagnostic arteriography for routine check-up of a cerebrovascular malformation
  • Patient who was informed and did not object to participating in the study

Exclusion criteria

  • NIHSS awareness score> or = 2
  • Pregnant woman
  • Protected major
  • Exam performed under general anesthesia

Treatment and study plan

Blood sample

Biological

Patients from 2 groups will undergo blood sample (during a blood sample for there care) and inflammation parameters will be measure the day of the stroke

Primary outcomes

  1. Inflammation parameters description

    Time frame: 1 day

    Inflammatory parameters such as CRP, IL-6, IL-10, HLA-DR, TNF-alpha, polymorphonuclear chemotaxis, CD-4, T-lymphocytes will be measure in blood sample

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: CONVASC-I

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Feb 1, 2021
Registry last updated
Feb 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.